Record Sales and Profits
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal
implant manufacturer, today announced its financial results for the
fourth quarter and year ended December 31, 2014.
Fourth Quarter:
- Worldwide sales were $128.8 million, an
11.8% increase from the fourth quarter of 2013
- Fourth quarter net income was $27.6
million
- Earnings per fully diluted share were
$0.29
- Non-GAAP Adjusted EBITDA was 36.7% of
sales
- Non-GAAP Adjusted diluted earnings per
share were $0.30
Full Year 2014:
- Worldwide sales were $474.4 million, up
9.2% over 2013
- Net income for the year was $92.5
million
- Fully diluted earnings per share were
$0.97
- Non-GAAP Adjusted EBITDA was 36.1% of
sales
- Non-GAAP Adjusted diluted earnings per
share were $1.01
“2014 was a great year for Globus Medical. Sales grew by 9.2%,
reaching $474.4 million, and full year Non-GAAP Adjusted EBITDA
increased by 140 basis points to 36.1% of sales. We launched 16 new
products, made steady progress on our robotics project, and
successfully completed the acquisition of Transplant Technologies
of Texas,” commented David Paul, Chairman and CEO. “This
performance was the result of continued execution of our strategy
of robust product innovation, sales force expansion, and
disciplined expense control. I am very proud of the performance of
our team in 2014 and remain confident in our ability to produce
industry leading growth and outstanding profitability.”
Dave Demski, President and COO, added, “Our fourth quarter sales
performance capped a strong year of profitable growth. Fourth
quarter worldwide sales were a record $128.8 million, an increase
of 11.8% over the fourth quarter of 2013. Non-GAAP Adjusted EBITDA
remained strong at 36.7% of sales.”
Net income for the year ending December 31, 2014 was $92.5
million, or $0.97 per diluted share, as compared to $68.6 million,
or $0.73 per diluted share, for 2013. Non-GAAP net income for the
year ending December 31, 2014 was $96.2 million, or $1.01 per
diluted share, as compared to $84.4 million, or $0.90 per diluted
share, for 2013. For the quarter ending December 31, 2014, net
income was $27.6 million, or $0.29 per diluted share, as compared
to $21.0 million, or $0.22 per diluted share, for 2013. Non-GAAP
net income for the quarter ending December 31, 2014 was $28.8
million, or $0.30 per diluted share, as compared to $24.0 million,
or $0.25 per diluted share, for 2013. The fourth quarter EPS was
positively impacted by $0.01 per share due to the extension of the
R&D tax credit for fiscal year 2014.
Non-GAAP Adjusted EBITDA for the year and quarter ending
December 31, 2014 were 36.1% and 36.7% of sales, respectively.
This compares to non-GAAP Adjusted EBITDA of 34.7% and 37.3% of
sales for year and quarter ending December 31, 2013,
respectively.
Cash, cash equivalents and marketable securities ended the year
at $304.1 million, increasing by $28.6 million during year. The
company remains debt free.
As previously announced, the company expects 2015 sales to be
approximately $510 million and earnings per fully diluted share to
be approximately $1.01 per share.
Conference Call Information
Globus Medical will hold a teleconference to discuss its 2014
fourth quarter and full year results with the investment community
at 5:30 p.m. Eastern Time today. Globus invites all interested
parties to join the call by dialing:
1-855-533-7141
United States Participants
1-720-545-0060
International Participants There is no pass code for the
teleconference.
For interested parties who do not wish to ask questions, the
teleconference will be webcast live and may be accessed through a
link on the Globus Medical website at
investors.globusmedical.com.
If you are unable to participate during the live teleconference,
the call will be archived until Wednesday, March 11, 2015. The
audio archive can be accessed by calling 1-855-859-2056 in the U.S.
or 1-404-537-3406 from outside the U.S. The passcode for the audio
replay is 2863-3216.
About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant
company based in Audubon, PA. The company was founded in 2003 by an
experienced team of professionals with a shared vision to create
products that enable surgeons to promote healing in patients with
musculoskeletal disorders.
Non-GAAP Financial Measures
To supplement our financial statements prepared in accordance
with U.S. generally accepted accounting principles (“U.S. GAAP”),
management uses certain non-GAAP financial measures. For example,
Adjusted EBITDA, which represents net income before interest
(income)/expense, net and other non-operating expenses, provision
for income taxes, depreciation and amortization, stock-based
compensation, changes in the fair value of acquisition-related
contingent consideration in connection with business acquisitions
and other acquisition related costs, provision for litigation and
provision for litigation - cost of goods sold, is useful as an
additional measure of operating performance, and particularly as a
measure of comparative operating performance from period to period,
as it is reflective of changes in pricing decisions, cost controls
and other factors that affect operating performance, and it removes
the effect of our capital structure, asset base, income taxes and
interest income and expense. Our management also uses Adjusted
EBITDA for planning purposes, including the preparation of our
annual operating budget and financial projections. In addition, for
the periods ended December 31, 2014 and for other comparative
periods, we are presenting non-GAAP net income and non-GAAP diluted
earnings per share, which represent net income and diluted earnings
per share, respectively, before provisions for litigation and
provision for litigation - cost of goods sold, net of the tax
effects of such provisions. We believe these non-GAAP measures are
also useful indicators of our operating performance, and
particularly as additional measures of comparative operative
performance from period to period as they remove the effects of
litigation, which we believe are not reflective of underlying
business trends. We also define the non-GAAP measure of Free Cash
Flow as the net cash provided by operating activities, adjusted for
the impact of restricted cash, less the cash impact of purchases of
property and equipment. We believe that this financial measure
provides meaningful information for evaluating our overall
financial performance for comparative periods as it facilitates an
assessment of funds available to satisfy current and future
obligations and fund acquisitions.
Adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings
per share and Free Cash Flow are not calculated in conformity with
U.S. GAAP. Non-GAAP financial measures have limitations as
analytical tools and should not be considered in isolation or as a
substitute for financial measures prepared in accordance with U.S.
GAAP. These measures do not include certain expenses that may be
necessary to evaluate our liquidity or operating results. Our
definitions of Adjusted EBITDA, non-GAAP net income, non-GAAP
diluted earnings per share and Free Cash Flow may differ from that
of other companies and therefore may not be comparable.
Safe Harbor Statements
All statements included in this press release other than
statements of historical fact are forward-looking statements and
may be identified by their use of words such as “believe,” “may,”
“might,” “could,” “will,” “aim,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “plan” and other similar terms.
These forward-looking statements are based on our current
assumptions, expectations and estimates of future events and
trends. Forward-looking statements are only predictions and are
subject to many risks, uncertainties and other factors that may
affect our businesses and operations and could cause actual results
to differ materially from those predicted. These risks and
uncertainties include, but are not limited to, factors affecting
our quarterly results, our ability to manage our growth, our
ability to sustain our profitability, demand for our products, our
ability to compete successfully (including without limitation our
ability to convince surgeons to use our products and our ability to
attract and retain sales and other personnel), our ability to
rapidly develop and introduce new products, our ability to develop
and execute on successful business strategies, our ability to
comply with laws and regulations that are or may become applicable
to our businesses, our ability to safeguard our intellectual
property, our success in defending legal proceedings brought
against us, trends in the medical device industry, general economic
conditions, and other risks. For a discussion of these and other
risks, uncertainties and other factors that could affect our
results, you should refer to the disclosure contained in our most
recent annual report on Form 10-K filed with the Securities and
Exchange Commission, including the sections labeled “Risk Factors”
and “Cautionary Note Concerning Forward-Looking Statements,” and in
our Forms 10-Q, Forms 8-K and other filings with the Securities and
Exchange Commission. These documents are available at www.sec.gov.
Moreover, we operate in an evolving environment. New risk factors
and uncertainties emerge from time to time and it is not possible
for us to predict all risk factors and uncertainties, nor can we
assess the impact of all factors on our business or the extent to
which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any
forward-looking statements. Given these risks and uncertainties,
readers are cautioned not to place undue reliance on any
forward-looking statements. Forward-looking statements contained in
this press release speak only as of the date of this press release.
We undertake no obligation to update any forward-looking statements
as a result of new information, events or circumstances or other
factors arising or coming to our attention after the date
hereof.
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME (unaudited)
Three Months Ended Year Ended (In thousands,
except per share amounts) December 31, 2014
December 31, 2013 December 31,
2014 December 31, 2013 Sales
$ 128,801 $ 115,245
$ 474,371 $ 434,459
Cost of goods sold
31,276 26,774
110,857 100,343
Gross profit 97,525
88,471
363,514 334,116 Operating
expenses: Research and development
8,404 6,418
31,687
26,870 Selling, general and administrative
47,709 45,669
187,798 182,518 Provision for litigation
1,768
4,637
5,667 23,055
Total operating
expenses 57,881 56,724
225,152
232,443
Operating income 39,644 31,747
138,362 101,673 Other income/(expense), net
(166
) 73
280 328
Income before income
taxes 39,478 31,820
138,642 102,001 Income tax
provision
11,840 10,835
46,157
33,389
Net income $ 27,638 $
20,985
$ 92,485 $ 68,612
Earnings per share: Basic
$ 0.29 $ 0.22
$ 0.98 $ 0.74 Diluted
$
0.29 $ 0.22
$ 0.97 $ 0.73
Weighted average shares outstanding: Basic
94,573
93,327
94,227 92,647 Diluted
95,670 94,629
95,457 94,192
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (unaudited)
December 31, December 31,
(In thousands, except par
value)
2014 2013 ASSETS Current assets: Cash
and cash equivalents
$ 82,265 $ 89,962 Restricted
cash
23,370 — Short-term marketable securities
146,439 148,962 Accounts receivable, net of allowances of
$1,647 and $1,581, respectively
75,430 62,414 Inventories
90,945 70,350 Prepaid expenses and other current assets
5,742 5,080 Income taxes receivable
5,772 2,723
Deferred income taxes
40,062 37,317
Total
current assets 470,025 416,808 Property
and equipment, net of accumulated depreciation of $118,544 and
$99,910, respectively
69,475 64,150 Long-term marketable
securities
75,347 36,528 Intangible assets, net
34,529 29,537 Goodwill
53,196 18,372 Other assets
975 909
Total assets $
703,547 $ 566,304
LIABILITIES AND
EQUITY Current liabilities: Accounts payable
15,904 10,073 Accounts payable to related-party
5,359
2,656 Accrued expenses
61,499 51,125 Income taxes payable
569 2,358 Business acquisition liabilities, current
6,081 1,730
Total current liabilities
89,412 67,942 Business acquisition
liabilities, net of current portion
20,195 15,528 Deferred
income taxes
5,166 6,385 Other liabilities
3,320
4,089
Total liabilities 118,093
93,944
Commitments and contingencies Equity:
Common stock; $0.001 par value. Authorized 785,000 shares; issued
and outstanding 94,706 and 93,443 shares at December 31, 2014 and
December 31, 2013, respectively
95 93 Additional paid-in
capital
175,242 153,987 Accumulated other comprehensive loss
(1,657 ) (1,009 ) Retained earnings
411,774
319,289
Total equity 585,454
472,360
Total liabilities and equity $
703,547 $ 566,304
GLOBUS MEDICAL,
INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH
FLOWS (unaudited) Year Ended December
31, December 31,
(In thousands)
2014 2013 Cash flows from operating
activities: Net income
$ 92,485 $ 68,612
Adjustments to reconcile net income to net cash provided by
operating activities: Depreciation and amortization
21,754
19,397 Amortization of premium on marketable securities
2,680 2,358 Provision for excess and obsolete inventories
6,962 8,212 Stock-based compensation
7,111 5,177
Allowance for doubtful accounts
318 693 Change in deferred
income taxes
(4,379 ) (14,858 ) (Increase)/decrease
in: Restricted cash
(23,370 ) — Accounts receivable
(12,667 ) (9,612 ) Inventories
(18,001
) (16,678 ) Prepaid expenses and other assets
(249
) (2,955 ) Increase/(decrease) in: Accounts payable
4,628 1,840 Accounts payable to related party
2,703
100 Accrued expenses and other liabilities
4,018 26,963
Income taxes payable/receivable
(4,821 ) 4,222
Net cash provided by operating activities 79,172
93,471
Cash flows from investing
activities: Purchases of marketable securities
(251,422
) (240,892 ) Maturities of marketable securities
184,567 40,560 Sales of marketable securities
27,737
13,637 Purchases of property and equipment
(24,754 )
(23,680 ) Acquisition of businesses
(36,128 ) (16,775
)
Net cash used in investing activities (100,000
) (227,150 )
Cash flows from financing
activities: Payment of business acquisition liabilities
(1,200 ) (1,300 ) Proceeds from issuance of common
stock
9,738 7,555 Excess tax benefit related to nonqualified
stock options
4,408 4,756
Net cash provided
by financing activities 12,946 11,011
Effect of foreign exchange rate on cash
185
230
Net decrease in cash and cash equivalents
(7,697 ) (122,438 ) Cash and cash equivalents,
beginning of period
89,962 212,400
Cash and
cash equivalents, end of period $ 82,265 $
89,962 Supplemental disclosures of cash flow
information: Interest paid
32 96 Income taxes paid
$
51,096 $ 38,719
The following tables reconcile GAAP to
Non-GAAP financial measures.
Non-GAAP Adjusted EBITDA Reconciliation Table:
(Unaudited)
Three Months Ended Year Ended December 31,
December 31, December 31, December
31,
(In thousands, except
percentages)
2014 2013 2014 2013 Net income
$
27,638 $ 20,985
$ 92,485 $ 68,612 Interest
income, net
(228 ) (131 )
(805 ) (467 )
Provision for income taxes
11,840 10,835
46,157
33,389 Depreciation and amortization
5,697 5,186
21,754 19,397 EBITDA
44,947
36,875
159,591 120,931 Stock-based compensation
1,900
1,312
7,111 5,177 Provision for litigation
1,768
4,637
5,667 23,055 Provision for litigation - cost of goods
sold
— —
— 1,260 Change in fair value of
acquisition-related contingent consideration
(1,353 )
110
(937 ) 120 Adjusted EBITDA
$
47,262 $ 42,934
$ 171,432
$ 150,543 Adjusted EBITDA as a percentage of sales
36.7 % 37.3 %
36.1 % 34.7 %
Non-GAAP Net Income Reconciliation
Table:
(Unaudited) Three Months Ended Year
Ended (In thousands) December 31, 2014
December 31, 2013 December 31,
2014 December 31, 2013 Net income
$ 27,638 $ 20,985
$ 92,485 $ 68,612
Provision for litigation, net of taxes
1,138 3,037
3,665 14,934 Provision for litigation - cost of goods sold,
net of taxes
— —
— 816 Non-GAAP
Net Income
$ 28,776 $ 24,022
$
96,150 $ 84,362
Non-GAAP Diluted Earnings Per Share
Reconciliation Table:
(Unaudited) Three Months Ended Year
Ended (Per share amounts) December 31,
2014 December 31, 2013 December
31, 2014 December 31, 2013 Diluted
earnings per share, as reported
$ 0.29 $ 0.22
$ 0.97 $ 0.73 Provision for litigation, net of taxes
0.01 0.03
0.04 0.16 Provision for litigation - cost
of goods sold, net of taxes
— —
—
0.01 Non-GAAP diluted earnings per share
$
0.30 $ 0.25
$ 1.01 $ 0.90
Non-GAAP Free Cash Flow Reconciliation
Table:
(Unaudited) Three Months Ended Year
Ended (In thousands) December 31, 2014
December 31, 2013 December 31,
2014 December 31, 2013 Net cash
provided by operating activities
$ 1,945 $ 32,658
$ 79,172 $ 93,471 Adjustment for impact of restricted
cash
23,370 —
23,370 — Purchases of property and
equipment
(9,095 ) (5,205 )
(24,754 )
(23,680 ) Non-GAAP free cash flow
$ 16,220 $
27,453
$ 77,788 $ 69,791
Liquidity and Capital
Resources:
(Unaudited) December 31, 2014
December 31, 2013 (In thousands) Cash and cash
equivalents
$ 82,265 $ 89,962 Short-term marketable
securities
146,439 148,962 Long-term marketable securities
75,347 36,528 Total cash, cash equivalents and
marketable securities
$ 304,051 $ 275,452
Available borrowing capacity under revolving credit facility
50,000 50,000 Working capital
$ 380,613 $
348,866
Globus Medical, Inc.Ed JoyceDirector, Investor
Relations610-930-1800investors@globusmedical.comwww.globusmedical.com
Globus Medical (NYSE:GMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
Globus Medical (NYSE:GMED)
Historical Stock Chart
From Apr 2023 to Apr 2024